• About us
  • Core Technology
  • Bio-Service
  • Investors
  • Careers
中文 English
  • About us
    • Introduction
    • Information
      • Announcement
      • Events
      • Corporate image
    • Management Team
      • Members
      • Consultants
    • Contact us
  • Core Technology
    • New medicine development platform
      • Skin diseases
        • ENERGI-F703 ENERGI-F701 ENERGI-F711
      • metabolic diseases
        • ENERGI-F702
      • Anti-inflammation
        • ENERGI-F704 ENERGI-F708
      • Diseases related to deficient mitochondrion
        • ENERGI-F705 ENERGI-F707
      • Others
        • ENERGI-F706 ENERGI-F709 ENERGI-F710
  • Bio-Service
    • Scientific products
      • Western Blot
      • Cell Culture Supplement
      • Protein Isolation
      • Protein Quantification
      • Dyes and Buffer
    • Supplier
      • Lumiprobe
      • Rigaku Reagents
    • Service
      • Quantitative MS and systematic biological analysis experiment service
      • Protein identity certification experiment service
      • Microarray and biological information analysis experiment service
  • Investors
    • Company
    • Financial information
      • Monthly revenue information
      • Financial report
    • Shareholders
      • Shareholders' Meeting
      • Dividend policy and dividend distribution
      • Public specification
      • Stock price information
      • Corporate briefing
      • Important information
      • Investment service window
      • Links
    • Corporate Governance
      • Member of the board
      • Functional committee
      • Various management measures
      • Internal audit
      • Head of Corporate Governance
    • Corporate social responsibility
      • Performance of corporate responsibility
      • Corporate Integrity Zone
      • Stakeholder
  • Careers

About us

  • >
  • About us
  • >
  • Information
  • >
  • Announcement
  • Introduction
  • Information
    • Announcement
    • Events
    • Corporate image
  • Management Team
    • Members
    • Consultants
  • Contact us
2024-09-02
Australian Patent Granted for "METHODS FORTREATING DIABETIC ULCER" Following PCT National Phase Entry
Energenesis Biomedical Co., Ltd. has received approval from IP Australia for the patent application titled ”METHODS FOR TREATING DIABETIC ULCER”,Application No. 2022256582.
Back
  • +886-2-26270835
  • +886-2-26270836
  • 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan (R.O.C.)
Copyright © 20204 ENERGENESIS BIOMEDICAL CO., LTD. All Rights Reserved. Design by choice